Literature DB >> 22589184

MALDI-TOF-MS analysis of sialylated glycans and glycopeptides using 4-chloro-α-cyanocinnamic acid matrix.

Maurice H J Selman1, Marcus Hoffmann, Gerhild Zauner, Liam A McDonnell, Crina I A Balog, Erdmann Rapp, André M Deelder, Manfred Wuhrer.   

Abstract

For MALDI analysis of glycans and glycopeptides, the choice of matrix is crucial in minimizing desialylation by mass spectrometric in-source and metastable decay. Here, we evaluated the potential of 4-chloro-α-cyanocinnamic acid (Cl-CCA) for MALDI-TOF-MS analysis of labile sialylated tryptic N-glycopeptides and released N- and O-glycans. Similar to DHB, but in contrast to CHCA, the Cl-CCA matrix allowed the analysis of sialylated N-glycans and glycopeptides in negative ion mode MALDI-TOF-MS. Dried droplet preparations of Cl-CCA provided microcrystals with a homogeneous spatial distribution and high shot-to-shot repeatability similar to CHCA, which simplified the automatic measurement and improved the resolution and mass accuracy. Interestingly, reflectron-positive ion mode analysis of 1-phenyl-3-methyl-5-pyrazolone (PMP)-labeled O-glycans with Cl-CCA revealed more complete profiles than with DHB and CHCA. In conclusion, we clearly demonstrate the high potential of this rationally designed matrix for glycomics and glycoproteomics.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22589184     DOI: 10.1002/pmic.201100498

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  20 in total

1.  Glycoproteomics Technologies in Glycobiotechnology.

Authors:  Kathirvel Alagesan; Marcus Hoffmann; Erdmann Rapp; Daniel Kolarich
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

2.  Data Independent Analysis of IgG Glycoforms in Samples of Unfractionated Human Plasma.

Authors:  Miloslav Sanda; Radoslav Goldman
Journal:  Anal Chem       Date:  2016-09-29       Impact factor: 6.986

3.  A Microarray-Matrix-assisted Laser Desorption/Ionization-Mass Spectrometry Approach for Site-specific Protein N-glycosylation Analysis, as Demonstrated for Human Serum Immunoglobulin M (IgM).

Authors:  Martin Pabst; Simon Karl Küster; Fabian Wahl; Jasmin Krismer; Petra S Dittrich; Renato Zenobi
Journal:  Mol Cell Proteomics       Date:  2015-03-23       Impact factor: 5.911

Review 4.  Glycosylation in cancer: its application as a biomarker and recent advances of analytical techniques.

Authors:  Yoshimi Haga; Koji Ueda
Journal:  Glycoconj J       Date:  2022-02-14       Impact factor: 2.916

5.  Mass Spectrometry-Based Methods for Immunoglobulin G N-Glycosylation Analysis.

Authors:  Siniša Habazin; Jerko Štambuk; Jelena Šimunović; Toma Keser; Genadij Razdorov; Mislav Novokmet
Journal:  Exp Suppl       Date:  2021

Review 6.  Advances in mass spectrometry-based glycoproteomics.

Authors:  Aiying Yu; Jingfu Zhao; Wenjing Peng; Alireza Banazadeh; Seth D Williamson; Mona Goli; Yifan Huang; Yehia Mechref
Journal:  Electrophoresis       Date:  2018-10-09       Impact factor: 3.535

7.  Sweet characterisation of prostate specific antigen using electrochemical lectin-based immunosensor assay and MALDI TOF/TOF analysis: Focus on sialic acid.

Authors:  Dominika Pihikova; Zuzana Pakanova; Marek Nemcovic; Peter Barath; Stefan Belicky; Tomas Bertok; Peter Kasak; Jan Mucha; Jan Tkac
Journal:  Proteomics       Date:  2016-04-13       Impact factor: 3.984

8.  Direct Analysis of Native N-Linked Glycans by IR-MALDESI.

Authors:  Crystal L Pace; David C Muddiman
Journal:  J Am Soc Mass Spectrom       Date:  2020-07-09       Impact factor: 3.109

9.  Analysis of Invertebrate and Protist N-Glycans.

Authors:  Alba Hykollari; Katharina Paschinger; Barbara Eckmair; Iain B H Wilson
Journal:  Methods Mol Biol       Date:  2017

Review 10.  Glycoproteomic analysis of antibodies.

Authors:  Gerhild Zauner; Maurice H J Selman; Albert Bondt; Yoann Rombouts; Dennis Blank; André M Deelder; Manfred Wuhrer
Journal:  Mol Cell Proteomics       Date:  2013-01-16       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.